Previous 10 |
Biora Therapeutics (NASDAQ:BIOR +4.5%) said on Thursday it had received a new patent related to its Drug Delivery System platform, which is under development. The company said the technology is applicable to any ingestible device, whether the device is for sampling, diagnostics, or ...
SAN DIEGO, May 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced a new patent related to its Drug Delivery System (DDS) platform under development. The USPTO has issued U.S. Patent No. 10,83...
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the Company’s management team will be presenting a corporate overview and participating in one-on-one meetings, upon re...
The following slide deck was published by Biora Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Biora Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Biora Therapeutics, Inc. (BIOR) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Chuck Padala – Managing Director, LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d’Esparbes – Chief Financial Officer Conference Call Particip...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...